Breast Cancer Research and Treatment

, Volume 12, Issue 3, pp 307–310

Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels

  • G. Bertelli
  • P. Pronzato
  • D. Amoroso
  • M. P. Cusimano
  • P. F. Conte
  • G. Montagna
  • S. Bertolini
  • R. Rosso
Brief communication

DOI: 10.1007/BF01811244

Cite this article as:
Bertelli, G., Pronzato, P., Amoroso, D. et al. Breast Cancer Res Tr (1988) 12: 307. doi:10.1007/BF01811244

Abstract

The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p<0.05).

Our results support the hypothesis of a partial agonist action of this antiestrogen, although general clinical practice suggests that tamoxifen-related thrombotic events are rare.

Key words

tamoxifenadjuvant endocrine therapyplasma lipidsantithrombin III

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • G. Bertelli
    • 1
  • P. Pronzato
    • 1
  • D. Amoroso
    • 1
  • M. P. Cusimano
    • 1
  • P. F. Conte
    • 1
  • G. Montagna
    • 1
    • 2
  • S. Bertolini
    • 1
    • 2
  • R. Rosso
    • 1
  1. 1.Istituto Nazionale per la Ricerca sul CancroDivisione di Oncologia MedicaGenovaItaly
  2. 2.Istituto Scientifico di Medicina InternaGenovaItaly